2 results
Approved WMOCompleted
Primary : to investigate the safety, tolerability and antiviral activity of multiple oral doses of JTK-652 administered for 4 weeks in subjects with chronic hepatitis C infection (genotype 1a, 1b)Secondary : to investigate the pharmacokinetics of…
Approved WMORecruiting
Phase 2:Primary ObjectivesTo determine the recommended Phase3 dose of mitapivat by evaluating the effect of 2 dose levels of mitapivat versus placebo on:• Anemia in subjects with sickle cell disease (SCD)• SafetySecondary ObjectivesTo evaluate the…